bioMérieux S.A (BIM) | Financial Analysis & Statements
bioMérieux S.A. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
5.6B
Total Liabilities
1.5B
Shareholders Equity
4.1B
Debt to Equity
0.36
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
bioMérieux S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.1B | 4.0B | 3.7B | 3.6B | 3.4B |
| Cost of Goods Sold | 1.8B | 1.8B | 1.6B | 1.6B | 1.4B |
| Gross Profit | 2.3B | 2.2B | 2.1B | 2.0B | 2.0B |
| Gross Margin % | 56.7% | 55.7% | 56.0% | 56.0% | 59.3% |
| Operating Expenses | |||||
| Research & Development | 507.4M | 491.5M | 460.1M | 446.6M | 385.8M |
| Selling, General & Administrative | 1.1B | 1.1B | 1.0B | 954.7M | 815.6M |
| Other Operating Expenses | -23.4M | -33.7M | -24.6M | -30.4M | -26.2M |
| Total Operating Expenses | 1.6B | 1.6B | 1.5B | 1.4B | 1.2B |
| Operating Income | 694.7M | 637.9M | 568.9M | 625.7M | 844.0M |
| Operating Margin % | 17.1% | 16.0% | 15.5% | 17.4% | 25.0% |
| Non-Operating Items | |||||
| Interest Income | 700.0K | 500.0K | 1.1M | 1.2M | 1.7M |
| Interest Expense | 15.8M | 16.0M | 15.8M | 4.1M | 9.1M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 525.7M | 579.3M | 437.5M | 580.5M | 774.5M |
| Income Tax | 128.8M | 154.3M | 114.5M | 140.1M | 175.6M |
| Effective Tax Rate % | 24.5% | 26.6% | 26.2% | 24.1% | 22.7% |
| Net Income | 396.9M | 425.1M | 322.8M | 440.5M | 598.2M |
| Net Margin % | 9.8% | 10.7% | 8.8% | 12.3% | 17.7% |
| Key Metrics | |||||
| EBITDA | 1.0B | 948.3M | 841.8M | 875.6M | 1.1B |
| EPS (Basic) | - | €3.67 | €3.03 | €3.84 | €5.08 |
| EPS (Diluted) | - | €3.64 | €3.01 | €3.82 | €5.06 |
| Basic Shares Outstanding | - | 117765668 | 118154233 | 117946146 | 118265377 |
| Diluted Shares Outstanding | - | 117765668 | 118154233 | 117946146 | 118265377 |
Income Statement Trend
bioMérieux S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 569.8M | 449.8M | 352.4M | 552.6M | 803.5M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 766.1M | 792.3M | 728.6M | 740.1M | 590.6M |
| Inventory | 959.7M | 1.0B | 908.5M | 737.2M | 620.0M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 2.5B | 2.5B | 2.2B | 2.2B | 2.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.8B | 1.7B | 1.6B | 1.4B | 1.3B |
| Goodwill | 1.9B | 2.0B | 1.9B | 2.2B | 1.8B |
| Intangible Assets | 401.5M | 492.0M | 528.7M | 624.9M | 411.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 10.2M | 9.1M | 7.4M | 12.9M | 12.5M |
| Total Non-Current Assets | 3.0B | 3.3B | 3.1B | 3.0B | 2.4B |
| Total Assets | 5.6B | 5.8B | 5.3B | 5.2B | 4.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 262.1M | 272.4M | 265.1M | 269.4M | 239.5M |
| Short-term Debt | 131.4M | 141.0M | 163.5M | 187.0M | 99.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 101.0M | 109.3M | 105.8M | 122.5M | 95.9M |
| Total Current Liabilities | 1.1B | 1.1B | 1.1B | 1.1B | 955.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 330.0M | 349.2M | 355.4M | 318.4M | 362.8M |
| Deferred Tax Liabilities | 26.0M | 25.7M | 11.1M | 53.0M | 60.3M |
| Other Non-Current Liabilities | - | 500.0K | -400.0K | 100.0K | -100.0K |
| Total Non-Current Liabilities | 404.0M | 424.6M | 419.4M | 412.6M | 485.5M |
| Total Liabilities | 1.5B | 1.6B | 1.5B | 1.5B | 1.4B |
| Equity | |||||
| Common Stock | 12.0M | 12.0M | 12.0M | 12.0M | 12.0M |
| Retained Earnings | 397.5M | 432.2M | 357.6M | 452.4M | 601.1M |
| Treasury Stock | 40.0M | 42.9M | 19.1M | 36.0M | 10.3M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 4.1B | 4.2B | 3.8B | 3.6B | 3.2B |
| Key Metrics | |||||
| Total Debt | 461.4M | 490.2M | 518.9M | 505.4M | 462.5M |
| Working Capital | 1.5B | 1.4B | 1.1B | 1.1B | 1.2B |
Balance Sheet Composition
bioMérieux S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 396.9M | 425.1M | 322.8M | 440.5M | 598.2M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 26.5M | 23.4M | 19.7M | 13.0M | 12.4M |
| Working Capital Changes | -74.7M | -50.4M | -206.7M | -165.8M | -47.0M |
| Operating Cash Flow | 364.1M | 417.4M | 149.0M | 276.6M | 573.7M |
| Investing Activities | |||||
| Capital Expenditures | -324.9M | -336.4M | -331.9M | -269.3M | -270.1M |
| Acquisitions | -5.2M | -13.4M | -158.7M | -43.3M | -3.3M |
| Investment Purchases | -1.0M | -1.2M | - | -10.5M | -400.0K |
| Investment Sales | - | - | 1.8M | - | - |
| Investing Cash Flow | -461.7M | -359.8M | -488.8M | -528.1M | -307.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | -157.2M | -3.8M |
| Dividends Paid | -106.1M | -100.2M | -100.2M | -101.2M | -73.1M |
| Debt Issuance | 33.6M | 9.8M | 38.9M | 67.7M | 18.2M |
| Debt Repayment | -63.2M | -84.6M | -73.7M | -53.4M | -68.3M |
| Financing Cash Flow | -137.2M | -175.0M | -135.0M | -244.2M | -127.0M |
| Free Cash Flow | 453.1M | 321.5M | 107.1M | 188.4M | 534.6M |
| Net Change in Cash | -234.8M | -117.4M | -474.8M | -495.7M | 139.4M |
Cash Flow Trend
bioMérieux S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
21.24
Forward P/E
13.90
Price to Book
2.04
Price to Sales
2.06
Profitability Ratios
Profit Margin
9.77%
Operating Margin
16.81%
Return on Equity
9.54%
Return on Assets
7.66%
Financial Health
Current Ratio
2.39
Debt to Equity
11.24
Beta
0.67
Per Share Data
EPS (TTM)
€3.34
Book Value per Share
€34.77
Revenue per Share
€34.49
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BIM | 8.4B | 21.24 | 2.04 | 9.54% | 9.77% | 11.24 |
| Eurofins Scientific | 10.8B | 24.24 | 3.08 | 9.50% | 6.51% | 96.84 |
| Lumibird S.A | 540.6M | 38.59 | 2.64 | 6.93% | 6.13% | 70.86 |
| Eurofins Cerep SAS | 79.7M | 12.94 | - | 8.74% | 15.86% | 0.10 |
| Klea Holding | 54.0M | 17.58 | 1.98 | 9.14% | 11.89% | 18.40 |
| Predilife S.A | 12.2M | - | - | -4,653.75% | 97.76% | -1.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.